Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

demonstrated encouraging potential in initial clinical studies," said David Tabagari, M.D., Ph.D., the head of Medulla Immunotherapy and Chemotherapy Clinic and principal investigator of the bavituximab breast cancer trial being conducted in the Republic of Georgia. "We are pleased to have the opportunity to conduct the first Phase II trial of this potentially valuable new approach to treating cancer."

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and about 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has recently received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol testing
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Bioquell, provider of germ-eliminating robots ... facilities around the world to decontaminate locations where ... the many places the hydrogen peroxide vapor technology ... Dallas and at the National Institutes of Health ... been utilized to decontaminate patient rooms, equipment, and ...
(Date:10/17/2014)... The North American Knowledge-based/Evidence-based Clinical Decision Support ... market in North America with analysis and forecast ... America is expected to reach around $283.3 million ... from 2013 to 2018. , Browse through the ... support system (CDSS) market, to get an idea ...
(Date:10/17/2014)... October 17, 2014 The report “Feed ... by Livestock (Swine, Cattle, Poultry, Aquatic Animals & Others), ... defines and segments the global feed antioxidant market with ... terms of value for the feed antioxidants. , The ... was estimated to be worth around $191.1 million in ...
(Date:10/17/2014)... October 17, 2014 According ... by Solutions (System Management, Parallel Environment, and ... and Licenses), by Platforms (Windows, Linux and ... - Global Forecast to 2019", by MarketsandMarkets, ... of the overall market, segmented by solutions, ...
Breaking Biology Technology:Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 2Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 3Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 4Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 5Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 6The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 2The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 3The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 4The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 5Feed Antioxidants Market Projected To Reach $238.5 Million by 2018 - New Report by MarketsandMarkets 2Feed Antioxidants Market Projected To Reach $238.5 Million by 2018 - New Report by MarketsandMarkets 3Feed Antioxidants Market Projected To Reach $238.5 Million by 2018 - New Report by MarketsandMarkets 4Clustering Software Market worth $2,940.8 Million in 2019 - New Report by MarketsandMarkets 2Clustering Software Market worth $2,940.8 Million in 2019 - New Report by MarketsandMarkets 3Clustering Software Market worth $2,940.8 Million in 2019 - New Report by MarketsandMarkets 4
... SAN FRANCISCO, March 22, 2011 Practice ... winner of Analyze This! part of Health 2.0,s Spring ... health records, available free through Microsoft,s Windows Azure Marketplace, ... his application could help identify and better control the ...
... "templated growth" technique for fabricating nanoribbons of epitaxial graphene ... that conduct current with almost no resistance. These ... made with conventional architectures and set the stage ... of the quantum properties of electrons. "We can ...
... Coinstar, Inc. (Nasdaq: CSTR ) ... consumer-driven healthcare technology company that develops and deploys ... EyeSite® product and the next-generation SoloHealth Station™.  Investment ... a leader in automated retail, Coinstar is continually ...
Cached Biology Technology:Disease Control App for Doctors Wins Health 2.0 Data Challenge, Analyze This! 2Disease Control App for Doctors Wins Health 2.0 Data Challenge, Analyze This! 3Disease Control App for Doctors Wins Health 2.0 Data Challenge, Analyze This! 4Templated growth technique produces graphene nanoribbons with metallic properties 2Templated growth technique produces graphene nanoribbons with metallic properties 3Templated growth technique produces graphene nanoribbons with metallic properties 4Coinstar to Invest in SoloHealth 2Coinstar to Invest in SoloHealth 3
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
(Date:10/16/2014)... Mary,s Virginia Institute of Marine Science have received ... Agency to identify the streams and wetlands most ... to help local governments and citizens conserve these ... a dataset of tidal-marsh observations first gathered by ... historical baseline can today,s researchers accurately map the ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... University of Tennessee, Knoxville, professor who is one of ... the world,s pre-eminent prize for ecology and environmental science. ... Studies in the Department of Ecology and Evolutionary Biology, ... The award is presented annually by the Government of ...
... other environmental factors led to the historically high number of dolphin ... released today. A team of biologists from several Gulf of ... their findings in the journal PLoS ONE . ... figure out why there were a high number of dolphin deaths, ...
... that has baffled researchers for more than 15 years: How does ... but dies on soybeans persist in fields that alternate between ... enzyme production in the rootworm gut. Their findings are described ... rotation declined in the middle of the 20th century as the ...
Cached Biology News:University of Tennessee professor wins world's top prize for ecology, environmental science 2University of Tennessee professor wins world's top prize for ecology, environmental science 3University of Tennessee professor wins world's top prize for ecology, environmental science 4Study points to causes of high dolphin deaths in Gulf of Mexico 2Team discovers how western corn rootworm resists crop rotation 2Team discovers how western corn rootworm resists crop rotation 3
Human peripheral blood eosinophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Biology Products: